Immunotherapeutic strategies for treating opioid use disorder and overdose

References

• Abuse S. Key substance use and mental health indicators in the United States: results from the 2019 national survey on drug use and health 2020. Accessed at: https://www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/2020NSDUHFFR1PDFW102121.pdf August 2022
   Google Scholar
• Centers for Disease Control and Prevention. State Unintentional Drug Overdose Reporting System (SUDORS). Atlanta, GA: US department of health and human services, CDC; [2022, June 27]. Accessed at: https://www.cdc.gov/drugoverdose/fatal/dashboard
   Google Scholar
• Appa A, Rodda LN, Cawley C, et al. Drug overdose deaths before and after shelter-in-place orders during the COVID-19 pandemic in San Francisco. JAMA network open. 2021;4(5):e2110452–e2110452.
   PubMed Web of Science ®Google Scholar
• DiGennaro C, Garcia GGP, Stringfellow EJ, et al. Changes in characteristics of drug overdose death trends during the COVID-19 pandemic. Int J Drug Policy. 2021;98:103392.
   PubMed Web of Science ®Google Scholar
• Tanz LJ, Dinwiddie AT, Snodgrass S, et al. Drug overdose deaths in 28 states and the District of Columbia: 2020 data from the state unintentional drug overdose reporting system 2022
   Google Scholar
• Centers for Disease Control and Prevention. Understanding the opioid overdose epidemic. Atlanta, GA: US department of health and human services, CDC; [2022, June 1]. Accessed at: https://www.cdc.gov/opioids/basics/epidemic.html.August.2022
   Google Scholar
• Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344–350.
   PubMed Web of Science ®Google Scholar
• IMS Institute for Healthcare Informatics. Use of opioid recovery medications. IMS institute for healthcare informatics [2016 September]. Accessed at: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/use-of-opioid-recovery-medications.pdf.in.August.2022
   Google Scholar
• Park TW, Larochelle MR, Saitz R, et al. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine. Addiction. 2020;115(5):924–932.
   PubMed Web of Science ®Google Scholar
• Williams AR, Samples H, Crystal S, et al. Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder. Am J Psychiatry. 20020;177(2):117–124.
   Google Scholar
• Comer SD, Cahill CM. Fentanyl: receptor pharmacology, abuse potential, and implications for treatment. Neurosci Biobehav Rev. 2019;106:49–57.
   PubMed Web of Science ®Google Scholar
• Armenian P, Vo KT, Barr-Walker J, et al. Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review. Neuropharmacology. 2018;134:121–132.
   PubMed Web of Science ®Google Scholar
• Schmid CL, Kennedy NM, Ross NC, et al. Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell. 2017;171(5):1165–1175.
   PubMed Web of Science ®Google Scholar
• Mattson CL, Tanz LJ, Quinn K, et al. Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019. Morbidity Mortality Weekly Rep. 2021;70(6):202.
   PubMed Web of Science ®Google Scholar
• Pardo B, Caulkins JP, Kilmer B, et al. The synthetic opioid surge in the United States. 2019 Santa Monica. CA: RAND Corporation. 2019
   Google Scholar
• Reuter P, Pardo B, Taylor J. Imagining a fentanyl future: some consequences of synthetic opioids replacing heroin. Int J Drug Policy. 2021;94:103086.
   PubMed Web of Science ®Google Scholar
• US Drug Enforcement Administration. 2020 national drug threat assessment, DEA DCT-DIR-008–21. 2021. Available at: https://www.dea.gov/documents/2021/03/02/2020-national-drug-threat-assessment. cited Aug 2022.
   Google Scholar
• Gilbert M, Dasgupta N. Silicon to syringe: cryptomarkets and disruptive innovation in opioid supply chains. Int J Drug Policy. 2017;46:160–167.
   PubMed Web of Science ®Google Scholar
• Gefen T, Vaya J, Khatib S, et al. The effect of haptens on protein-carrier immunogenicity. Immunology. 2015;144(1):116–126.
   PubMed Web of Science ®Google Scholar
• Heekin RD, Shorter D, Kosten TR. Current status and future prospects for the development of substance abuse vaccines. Expert Rev Vaccines. 2017;16(11):1067–1077.
   PubMed Web of Science ®Google Scholar
• Pravetoni M. Biologics to treat substance use disorders: current status and new directions. Hum Vaccin Immunother. 2016;12(12):3005–3019.
   PubMed Web of Science ®Google Scholar
• Crouse B, Hicks D, Pravetoni M. Investigating the role of interleukin-4 in anti-opioid vaccine efficacy. The Journal of Immunology. 2022; 208 (supplement):123–12.
   Web of Science ®Google Scholar
• Pulendran B, Arunachalam S, O’Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021;20(6):454–475.
   PubMed Web of Science ®Google Scholar
• Cano RLE, Lopera HDE. Introduction to T and B lymphocytes Anaya, Juan-Manuel, Shoenfield, Yehuda, Rojas-Villarraga, Adriana, Levy, Roger, Cervera, Ricard. In: Autoimmunity: from bench to bedside 1 . Bogota, Colombia: El Rosario University Press; 2013:77–97.
   Google Scholar
• Pichichero ME. Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum Vaccin Immunother. 2013;9(12):2505–2523.
   PubMed Web of Science ®Google Scholar
• Pravetoni M, Comer SD. Development of vaccines to treat opioid use disorders and reduce incidence of overdose. Neuropharmacology. 2019;158:107662.
   PubMed Web of Science ®Google Scholar
• Shen XY, Orson FM, Kosten TR. Vaccines against drug abuse. Clin Pharmacol Ther. 2012;91(1):60–70.
   PubMed Web of Science ®Google Scholar
• Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 2019;32(2):e00084–18.
   PubMed Web of Science ®Google Scholar
• Chaudary S, Kaur A, Atri M, et al. Recent advancements in the development of nicotine vaccines: a systematic review. An Public Health Res. 2020;7(2):205–450.
   Google Scholar
• Pentel PR, LeSage MG. New directions in nicotine vaccine design and use. Adv Pharmacol. 2014;69:553–580.
   PubMedGoogle Scholar
• Kelcher AMH, Baehr CA, Hamid FA, et al. Contribution of antibody-mediated effector functions to the mechanism of efficacy of vaccines for opioid use disorders. J Immunol. 2021;207(3):860–867.
   PubMed Web of Science ®Google Scholar
• Laudenbach M, Baruffaldi F, Vervacke JS, et al., The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse. J Immunol. 2015. 194(12): 5926–5936.
   PubMed Web of Science ®Google Scholar
• Cerny EH, Levy R, Mauel J, et al. Preclinical development of a vaccine ‘against smoking.’ Oncol Res Treat. 2002;25(5):406–411.
   Google Scholar
• Desai RI, Bergman J. Effects of the nanoparticle-based vaccine, SEL-068, on nicotine discrimination in squirrel monkeys. Neuropsychopharmacology. 2015;40(9):2207–2216.
   PubMed Web of Science ®Google Scholar
• Maurer P, Jennings GT, Willers J, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol. 2005;35(7):2031–2040.
   PubMed Web of Science ®Google Scholar
• Pravetoni M, Keyler DE, Raleigh MD, et al. Vaccination against nicotine alters the distribution of nicotine delivered via cigarette smoke inhalation to rats. Biochem Pharmacol. 2011;81(9):1164–1170.
   PubMed Web of Science ®Google Scholar
• Satoskar SD, Keyler DE, LeSage MG, et al. Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats. Int Immunopharmacol. 2003;3(7):957–970.
   PubMed Web of Science ®Google Scholar
• Hieda Y, Keyler DE, Ennifar S, et al. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol. 2000;22(10):809–819.
   PubMed Web of Science ®Google Scholar
• Lindblom N, De Villiers SHL, Kalayanov G, et al. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration. 2002;69(3):254–260.
   PubMed Web of Science ®Google Scholar
• LeSage MG, Keyler DE, Hieda Y, et al. Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology (Berl). 2006;184(3):409–416.
   PubMed Web of Science ®Google Scholar
• Fahim RE, Kessler PD, Kalnik MW. Therapeutic vaccines against tobacco addiction. Expert Rev Vaccines. 2013;12(3):333–342.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.Gov [Internet]. Bethesda (MD): National Library of Medicine. 2000 Feb 29. identifier nct00633321, study of TA-NIC to assess the efficacy and safety of a vaccine to aid in smoking cessation. and pharmacodynamics of SEL-068 vaccine in smokers and non-smokers, 2008, Mar 12 [cited Aug 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT00633321
   Google Scholar
• Tonstad S, Heggen E, Giljam H. Lagerbäck, et al. Niccine®, a nicotine vaccine, for relapse prevention: a phase II, randomized, placebo-controlled. Multicenter Clinical Trial Nicotine Tob Res. 2013;15(9):1492–1501.
   PubMed Web of Science ®Google Scholar
• Cornuz J, Zwahlen S, Jungi WF, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PloS one. 2008;3(6):e2547.
   PubMed Web of Science ®Google Scholar
• Hatsukami DK, Rennard S, Jorenby D, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther. 2005;78(5):456–467.
   PubMed Web of Science ®Google Scholar
• Hatsukami DK, Jorenby DE, Gonzales D, et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther. 2011;89(3):392–399.
   PubMed Web of Science ®Google Scholar
• Wagena EJ, de Vos A, Horwith G, et al. The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial. Nicotine Tob Res. 2008;10(1):213–218.
   PubMed Web of Science ®Google Scholar
• Hartmann-Boyce J, Stead LF, Cahill K, et al. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2012 reviews. Addiction, 2013. Addiction (Abingdon, England). 2013;108(10):1711–1721.
   PubMed Web of Science ®Google Scholar
• Pryde DC, Jones LH, Gervais DP, et al. Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice. PloS one. 2013;8(10):e76557.
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Thorn J, Gervais DP, et al. Anti-nicotine vaccines: comparison of adjuvanted CRM197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates. Int Immunopharmacol. 2015;29(2):663–671.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.Gov [Internet]. Bethesda (MD): National Library of Medicine. 2000 Feb 29. Identifier NCT01478893, Safety and Pharmacodynamics of SEL-068 Vaccine in Smokers and Non-Smokers, 2011, Nov 23 [cited Aug 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT01478893
   Google Scholar
• Kinsey BM, Kosten TR, Orson FM. Anti-cocaine vaccine development. Expert Rev Vaccines. 2010;9(9):1109–1114.
   PubMed Web of Science ®Google Scholar
• Carrera MRA, Ashley JA, Parsons LH, et al. Suppression of psychoactive effects of cocaine by active immunization. Nature. 1995;378(6558):727–730.
   PubMed Web of Science ®Google Scholar
• Carrera MRA, Ashley JA, Wirsching P, et al. A second-generation vaccine protects against the psychoactive effects of cocaine Proceedings of the National Academy of Sciences. 2001 ; 98(4):1988–1992.
   PubMed Web of Science ®Google Scholar
• Carrera MRA, Ashley JA, Zhou B, Wirsching, et al. Cocaine vaccines: antibody protection against relapse in a rat model. Proceedings of the National Academy of Sciences. 2000 ; 97(11),6202–6206.
   PubMed Web of Science ®Google Scholar
• Fox BS, Kantak KM, Edwards MA, et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med. 1996;2(10):1129–1132.
   PubMed Web of Science ®Google Scholar
• Kantak KM, Collins SL, Lipman EG, et al. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl). 2000;148(3):251–262.
   PubMed Web of Science ®Google Scholar
• Kantak KM, Collins SL, Bond J, et al. Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010. Psychopharmacology (Berl). 2001;153(3):334–340.
   PubMed Web of Science ®Google Scholar
• Koetzner L, Deng S, Sumpter TL, et al. Titer-dependent antagonism of cocaine following active immunization in rhesus monkeys. J Pharmacol Exp Ther. 2001;296(3):789–796.
   PubMed Web of Science ®Google Scholar
• Hrafnkelsdottir K, Valgeirsson J, Gizurarson S. Induction of protective and specific antibodies against cocaine by intranasal immunisation using a glyceride adjuvant. Biol Pharm Bull. 2005;28(6):1038–1042.
   PubMed Web of Science ®Google Scholar
• Hicks MJ, Kaminsky SM, De BP, et al. Fate of systemically administered cocaine in nonhuman primates treated with the dAd5GNE anticocaine vaccine. Hum Gene Ther Clin Dev. 2014;25(1):40–49.
   PubMed Web of Science ®Google Scholar
• Maoz A, Hicks MJ, Vallabhjosula S, et al. Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter. Neuropsychopharmacology. 2013;38(11):2170–2178.
   PubMed Web of Science ®Google Scholar
• Wee S, Hicks MJ, De BP, et al. Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects. Neuropsychopharmacology. 2012;37(5):1083–1091.
   PubMed Web of Science ®Google Scholar
• Kosten TR, Gonsai K, St Clair Roberts J, et al. Phase II human study of cocaine vaccine TA-CD. 2002, June. In CPDD Annual Meeting, Quebec City.
   Google Scholar
• Kosten TR, Biegel D. Therapeutic vaccines for substance dependence. Expert Rev Vaccines. 2002;1(3):365–371.
   Google Scholar
• Martell BA, Mitchell E, Poling J, et al. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry. 2005;58(2):158–164.
   PubMed Web of Science ®Google Scholar
• Martell BA, Orson FM, Poling J, et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry. 2009;66(10):1116–1123.
   PubMed Web of Science ®Google Scholar
• Haney M, Gunderson EW, Jiang H, et al. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry. 2010;67(1):59–65.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.Gov [Internet]. Bethesda (MD): National Library of Medicine. 2000 Feb 29. Identifier NCT02455479, Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-Dependent Individuals, 2015, May 27 7 [cited Aug 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT02455479
   Google Scholar
• Shen XY, Kosten TA, Lopez AY, et al. A vaccine against methamphetamine attenuates its behavioral effects in mice. Drug Alcohol Depend. 2013;129(1–2):41–48.
   PubMed Web of Science ®Google Scholar
• Haile CN, Kosten TA, Shen XY, et al. Altered methamphetamine place conditioning in mice vaccinated with a succinyl-methamphetamine-tetanus-toxoid vaccine. Am J Addict. 2015;24(8):748–755.
   PubMed Web of Science ®Google Scholar
• Keller CM, Spence AL, Stevens MW, et al. Effects of a methamphetamine vaccine, IXT-v100, on methamphetamine-related behaviors. Psychopharmacology (Berl). 2020;237(3):655–667.
   PubMed Web of Science ®Google Scholar
• Miller ML, Moreno AY, Aarde SM, et al. A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats. Biol Psychiatry. 2013;73(8):721–728.
   PubMed Web of Science ®Google Scholar
• Miller ML, Aarde SM, Moreno AY, et al. Effects of active anti-methamphetamine vaccination on intravenous self-administration in rats. Drug Alcohol Depend. 2015;153:29–36.
   PubMed Web of Science ®Google Scholar
• Moreno AY, Mayorov AV, Janda KD. Impact of distinct chemical structures for the development of a methamphetamine vaccine. J Am Chem Soc. 2011;133(17):6587–6595.
   PubMed Web of Science ®Google Scholar
• Collins KC, Schlosburg JE, Lockner JW, et al. Lipid tucaresol as an adjuvant for methamphetamine vaccine development. Chem Comm. 2014;50(31):4079–4081.
   PubMed Web of Science ®Google Scholar
• Collins KC, Schlosburg JE, Bremer PT, et al. Methamphetamine vaccines: improvement through hapten design. J Med Chem. 2016;59(8):3878–3885.
   PubMed Web of Science ®Google Scholar
• Stevens MW, Gunnell MG, Tawney R, et al. Optimization of a methamphetamine conjugate vaccine for antibody production in mice. Int Immunopharmacol. 2016;35:137–141.
   PubMed Web of Science ®Google Scholar
• Spector S, Berkowitz B, Flynn EJ, et al. Antibodies to morphine, barbiturates, and serotonin. Pharmacol Rev. 1973;25(2):281–291.
   PubMed Web of Science ®Google Scholar
• Bonese KF, Wainer BH, Fitch FW, et al. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature. 1974;252(5485):708–710.
   PubMed Web of Science ®Google Scholar
• Kosten TA, Shen XY, O’Malley PW. Kinsey, et al. A Morphine Conjugate Vaccine Attenuates the Behavioral Effects of Morphine in Rats Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2013;45:223–229.
   Google Scholar
• Raleigh MD, Pentel PR. Vaccines for opioid addiction Montoya, Ivan. In: Biologics to treat substance use disorders (Cham: Springer). 2016. p. 37–63.
   Google Scholar
• Truong TT, Kosten TR. Current status of vaccines for substance use disorders: a brief review of human studies. J Neurol Sci. 2021;434:120098.
   PubMed Web of Science ®Google Scholar
• Schlosburg JE, Vendruscolo LF, Bremer PT, et al. Dynamic vaccine blocks relapse to compulsive intake of heroin. Proceedings of the National Academy of Sciences. 110(22),9036–9041.
   PubMed Web of Science ®Google Scholar
• Raleigh MD, Peterson SJ, Laudenbach M, et al. Safety and efficacy of an oxycodone vaccine: addressing some of the unique considerations posed by opioid abuse. PLoS One. 2017;12(12):e0184876.
   PubMed Web of Science ®Google Scholar
• Bremer PT, Kimishima A, Schlosburg JE, et al. Combatting synthetic designer opioids: a conjugate vaccine ablates lethal doses of fentanyl class drugs. Angew Chem. 2016;128(11):3836–3839.
   Google Scholar
• Tenney RD, Blake S, Bremer PT, et al. Vaccine blunts fentanyl potency in male rhesus monkeys. Neuropharmacology. 2019;158:107730.
   PubMed Web of Science ®Google Scholar
• Stone AE, Scheuermann SE, Haile CN, et al. Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge. Npj Vaccines. 2021;6(1):1–11.
   PubMed Web of Science ®Google Scholar
• Hwang CS, Smith LC, Natori Y, et al. Efficacious vaccine against heroin contaminated with fentanyl. ACS Chem Neurosci. 2018;9(6):1269.
   PubMed Web of Science ®Google Scholar
• Raleigh MD, Baruffaldi F, Peterson SJ, et al. A fentanyl vaccine alters fentanyl distribution and protects against fentanyl-induced effects in mice and rats. J Pharmacol Exp Ther. 2019;368(2):282–291.
   PubMed Web of Science ®Google Scholar
• Eubanks LM, Blake S, Natori Y, et al. A highly efficacious carfentanil vaccine that blunts opioid-induced antinociception and respiratory depression. ACS Chem Biol. 2021;16(2):277–282.
   PubMed Web of Science ®Google Scholar
• Baehr C, Robinson C, Kassick A. et al. Preclinical efficacy and selectivity of vaccines targeting fentanyl, alfentanil, sufentanil, and acetylfentanyl in rats. ACS omega. 2022;7(19): 16584–92.
   PubMed Web of Science ®Google Scholar
• Sulima A, Jalah R, Antoline JF, et al. A stable heroin analogue that can serve as a vaccine hapten to induce antibodies that block the effects of heroin and its metabolites in rodents and that cross-react immunologically with related drugs of abuse. J Med Chem. 2018;61(1):329–343.
   PubMed Web of Science ®Google Scholar
• Torres OB, Matyas GR, Rao M, et al. Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant. Npj Vaccines. 2017;2(1):1–8.
   PubMedGoogle Scholar
• Beck Z, Torres OB, Matyas GR, et al. Immune response to antigen adsorbed to aluminum hydroxide particles: effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex. J Control Release. 2018;275:12–19.
   PubMed Web of Science ®Google Scholar
• Bremer PT, Janda KD, Barker EL. Conjugate vaccine immunotherapy for substance use disorder. Pharmacol Rev. 2017;69(3):298–315.
   PubMed Web of Science ®Google Scholar
• Raleigh MD, Pravetoni M, Harris AC, et al. Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats. J Pharmacol Exp Ther. 2013;344(2):397–406.
   PubMed Web of Science ®Google Scholar
• Raleigh MD, Pentel PR, LeSage MG. Pharmacokinetic correlates of the effects of a heroin vaccine on heroin self-administration in rats. PLoS One. 2014;9(12):e115696.
   PubMed Web of Science ®Google Scholar
• Raleigh MD, Laudenbach M, Baruffaldi F, et al. Opioid dose-and route-dependent efficacy of oxycodone and heroin vaccines in rats. J Pharmacol Exp Ther. 2018;365(2):346–353.
   PubMed Web of Science ®Google Scholar
• Pravetoni M, Le Naour M, Tucker AM, et al. Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens. J Med Chem. 2013;56(3):915–923.
   PubMed Web of Science ®Google Scholar
• Kimishima A, Wenthur CJ, Zhou B, et al. An advance in prescription opioid vaccines: overdose mortality reduction and extraordinary alteration of drug half-life. ACS Chem Biol. 2017;12(1):36–40.
   PubMed Web of Science ®Google Scholar
• Nguyen JD, Hwang CS, Grant Y, et al. Prophylactic vaccination protects against the development of oxycodone self-administration. Neuropharmacology. 2018;138:292–303.
   PubMed Web of Science ®Google Scholar
• Pravetoni M, Pentel PR, Potter DN, et al., Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats. PloS one. 2014. 9(7): e101807.
   PubMed Web of Science ®Google Scholar
• Laudenbach M, Baruffaldi F, Robinson C, et al. Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose. Sci Rep. 2018;8(1):1–12.
   PubMedGoogle Scholar
• Akbarzadeh A, Mehraby M, Zarbakhsh M, et al. Design and synthesis of a morphine-6-succinyl-bovine serum albumin hapten for vaccine development. Biotechnol Appl Biochem. 1999;30(2):139–145.
   PubMedGoogle Scholar
• Akbarzadeh A, Norouzian D, Farhangi A, et al. Immunotherapy of 347 volunteer outpatient morphine addicts by human therapeutic morphine vaccine in Kermanshah province of Iran. J Pharmacol Toxicol. 2009;4(1):30–35.
   Google Scholar
• ClinicalTrials.Gov [Internet]. Bethesda (MD): National Library of Medicine. 2000 Feb 29. Identifier NCT04458545, Clinical Trials of Multivalent Opioid Vaccine Components, 2020, Jul 7 [cited Aug 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT04458545
   Google Scholar
• Carrera MRA, Ashley JA, Hoffman TZ, et al. Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem. 2004;12(3):563–570.
   PubMed Web of Science ®Google Scholar
• Keyler DE, Roiko SA, Benlhabib E, et al. Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose-and affinity-response relationships. Drug Metab Dispos. 2005;33(7):1056–1061.
   PubMed Web of Science ®Google Scholar
• Carrera MRA, Trigo JM, Wirsching P, et al. Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose. Pharmacol Biochem Behav. 2005;81(4):709–714.
   PubMed Web of Science ®Google Scholar
• Norman AB, Norman MK, Buesing WR, et al. The effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-administration in rats. J Pharmacol Exp Ther. 2009;328(3):873–881.
   PubMed Web of Science ®Google Scholar
• Gentry WB, Laurenzana EM, Williams DK, et al. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int Immunopharmacol. 2006;6(6):968–977.
   PubMed Web of Science ®Google Scholar
• Baehr C, Kelcher AH, Khaimraj A, et al. Monoclonal antibodies counteract opioid-induced behavioral and toxic effects in mice and rats. J Pharmacol Exp Ther. 2020;375(3):469–477.
   PubMed Web of Science ®Google Scholar
• Bogen IL, Boix F, Nerem E, et al. A monoclonal antibody specific for 6-monoacetylmorphine reduces acute heroin effects in mice. J Pharmacol Exp Ther. 2014;349(3):568–576.
   PubMed Web of Science ®Google Scholar
• Kvello AMS, Andersen JM, Øiestad EL, et al. Pharmacological effects of a monoclonal antibody against 6-monoacetylmorphine upon heroin-induced locomotor activity and pharmacokinetics in mice. J Pharmacol Exp Ther. 2016;358(2):181–189.
   PubMed Web of Science ®Google Scholar
• Hardin JS, Wessinger WD, Wenger GR, et al. A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats. J Pharmacol Exp Ther. 2002;302(1):119–126.
   PubMed Web of Science ®Google Scholar
• Stevens MW, Henry RL, Owens SM, et al. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers. MAbs. 2014;6(6):1649–1656.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.Gov [Internet]. Bethesda (MD): National Library of Medicine. 2000 Feb 29. Identifier NCT03336866, Study of Antibody for Methamphetamine Outpatient Therapy (STAMPOUT), 2017, Nov 8 [cited Sept 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT03336866
   Google Scholar
• Baehr CA, Wu MM, Pandit SG, et al. Pharmacological profiling of antifentanyl monoclonal antibodies in combination with naloxone in pre-and postexposure models of fentanyl toxicity. J Pharmacol Exp Ther. 2022;381(2):129–136.
   PubMed Web of Science ®Google Scholar
• Shaffer L (2021). Using vaccines to harness the immune system and fight drugs of abuse Proceedings of the National Academy of Sciences. 118(52), e2121094118.
   PubMed Web of Science ®Google Scholar
• Baruffaldi F, Kelcher AH, Laudenbach M, et al. Preclinical efficacy and characterization of candidate vaccines for treatment of opioid use disorders using clinically viable carrier proteins. Mol Pharm. 2018;15(11):4947–4962.
   PubMedGoogle Scholar
• Crouse B, Zhang L, Robinson C, et al. Housing conditions and microbial environment do not affect the efficacy of vaccines for treatment of opioid use disorders in mice and rats. Hum Vaccin Immunother. 2021;17(11):4383–4392.
   PubMed Web of Science ®Google Scholar
• O’Connor AM, Cousins G, Durand L, et al. Retention of patients in opioid substitution treatment: a systematic review. PloS one. 2020;15(5):e0232086.
   PubMed Web of Science ®Google Scholar
• Timko C, Schultz NR, Cucciare MA, et al. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22–35.
   PubMed Web of Science ®Google Scholar
• Wu LT, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117–127.
   PubMed Web of Science ®Google Scholar